Emerson Collective

Plus: New fundings for Exsilio, TwoStep and Augustine

Plus: Early-stage financings for InduPro, Syntis and Moleculent; J.P. Morgan closes its life sciences vehicle; and a new fund for spinal injury

Plus: Emerson Collective spins out Yosemite with $200M cancer fund, first commercial patient receives Sarepta’s DMD gene therapy, and more

Behind the lead asset are other technologies from co-founder Crystal Mackall to overcome common mechanisms of cancer drug resistance

Plus: Keytruda approved for adjuvant NSCLC and updates for AZ’s Evusheld, BMS’s Breyanzi, Magenta, Theonys and more

Fresh off a $220M series B, ArsenalBio scores its second pharma partnership for cancer T cell therapies

Plus Arsenal raises $220M and updates from Roche, Phoremost, Synlogic and more

Backed with $70M, the start-up unites Trillium alumni with academics to discover more phagocytosis targets for cancer

GV-backed, Bay Area biotech focusing on immuno-oncology for internal gene editing pipeline while mulling partnerships elsewhere

An innovation showcase of protein degraders, RNA therapeutics, delivery vectors and gene modifiers